drugset / Trial / NCT02320448

Treating Peritoneal Carcinomatosis With PIPAC

NCT02320448 ↗

Phase 2 Completed 35 enrolled Michael Bau Mortensen
NaSingle-groupOpen-labelTreatment

Summary

This is a feasibility study that aims to evaluate whether PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a safe and feasible treatment in Danish patients with peritoneal cancer.

Timeline

Start
2015-03
Primary completion
2017-08
Completion
2017-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 7.5 mg/m2 Other
Subject Doxorubicin Other / unclassified 1.5 mg/m2 Other
Subject Oxaliplatin Small molecule 92 mg/m2 Other